CQS
ALNY icon

Credential Qtrade Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Credential Qtrade Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed -$564 – 359
2021
Q1 		$564 Buy
+4
New +$602 ﹤0.01% 379

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credential Qtrade Securities's ALNY Position: Q2 2021 in Review

Credential Qtrade Securities sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 4 shares — an estimated $564 sold.

Credential Qtrade Securities first reported a position in ALNY in Q1 2021 and held it in 1 quarter. The position peaked at $564 in Q1 2021. 401 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

  • Credential Qtrade Securities reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Credential Qtrade Securities sold 4 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $564.
  • Credential Qtrade Securities first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Credential Qtrade Securities's Alnylam Pharmaceuticals position peaked at $564 in Q1 2021.
  • 401 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on Credential Qtrade Securities's 13F filing for Q2 2021, filed 21 Jul 2025.